Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT113 plus pembrolizumab versus pembrolizumab in first-line HPV16-positive PD-L1–positive recurrent/metastatic HNSCC
2020-001400-41Phase 2Active
- Sponsor
- BioNTech SE
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing BNT113 + pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoint: Safety Run-In Phase (Part A) primary endpoints. Started Nov 2020; status: active.
02
Drugs
BNT113pembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-001400-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001400-41.